These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23555019)

  • 1. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
    Xie X; Ma YT; Yang YN; Li XM; Ma X; Fu ZY; Zheng YY; Chen BD; Liu F
    PLoS One; 2013; 8(3):e59344. PubMed ID: 23555019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
    Zou JJ; Xie HG; Chen SL; Tan J; Lin L; Zhao YY; Xu HM; Lin S; Zhang J; Wang GJ
    Eur J Clin Pharmacol; 2013 Apr; 69(4):771-7. PubMed ID: 23001453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
    Wu H; Qian J; Sun A; Wang Q; Ge J
    Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
    Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
    Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
    Wu Y; Zhang XX; Tian L; Jiang JJ; Xu L; Huang YL; Liu H; Li YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):377-385. PubMed ID: 28511321
    [No Abstract]   [Full Text] [Related]  

  • 9. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
    Siller-Matula JM; Delle-Karth G; Lang IM; Neunteufl T; Kozinski M; Kubica J; Maurer G; Linkowska K; Grzybowski T; Huber K; Jilma B
    J Thromb Haemost; 2012 Apr; 10(4):529-42. PubMed ID: 22260716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
    Carlquist JF; Knight S; Horne BD; Huntinghouse JA; Rollo JS; Muhlestein JB; May H; Anderson JL
    Thromb Haemost; 2013 Apr; 109(4):744-54. PubMed ID: 23364775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
    Sawada T; Shinke T; Shite J; Honjo T; Haraguchi Y; Nishio R; Shinohara M; Toh R; Ishida T; Kawamori H; Kozuki A; Inoue T; Hariki H; Hirata K
    Circ J; 2011; 75(1):99-105. PubMed ID: 21099121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
    Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
    Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
    Mega JL; Simon T; Collet JP; Anderson JL; Antman EM; Bliden K; Cannon CP; Danchin N; Giusti B; Gurbel P; Horne BD; Hulot JS; Kastrati A; Montalescot G; Neumann FJ; Shen L; Sibbing D; Steg PG; Trenk D; Wiviott SD; Sabatine MS
    JAMA; 2010 Oct; 304(16):1821-30. PubMed ID: 20978260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.
    Mejin M; Tiong WN; Lai LY; Tiong LL; Bujang AM; Hwang SS; Ong TK; Fong AY
    Int J Clin Pharm; 2013 Aug; 35(4):621-8. PubMed ID: 23661171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
    Luo Y; Zhao YT; Verdo A; Qi WG; Zhang DF; Hu B
    J Int Med Res; 2011; 39(5):2012-9. PubMed ID: 22118006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation.
    Nakata T; Miyahara M; Nakatani K; Wada H; Tanigawa T; Komada F; Hoshino K; Aoki T; Nishimura Y; Tamaru S; Ito M; Nishikawa M;
    Circ J; 2013; 77(6):1436-44. PubMed ID: 23470885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial.
    Xie X; Ma YT; Yang YN; Li XM; Zheng YY; Ma X; Fu ZY; Ba Bayinsilema ; Li Y; Yu ZX; Chen Y; Chen BD; Liu F; Huang Y; Liu C; Baituola G
    Int J Cardiol; 2013 Oct; 168(4):3736-40. PubMed ID: 23850318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.